Literature DB >> 19628788

Tissue factor and cancer stem cells: is there a linkage?

Chloe Milsom1, Nathalie Magnus, Brian Meehan, Khalid Al-Nedawi, Delphine Garnier, Janusz Rak.   

Abstract

A common feature in the progression of multiple human malignancies is the protracted deregulation of the coagulation system, often referred to as cancer coagulopathy. Indeed, cancer cells and their vascular stroma often exhibit procoagulant properties, of which deregulation of tissue factor (TF) expression is a notable, although not the sole example. These changes can be traced to oncogenic influences affecting epidermal growth factor receptor (EGFR), EGFRvIII, K-ras, p53, PTEN, and probably many other proto-oncogenes and tumor suppressors in tumor parenchyma. Cancer stem cells (CSCs)/tumor initiating cells (TICs) are thought to represent the primary target and the main cellular effector through which oncogenic mutations exert their tumor-inducing effects. In so doing, CSCs/TICs depend on interactions with the tumor vasculature, which forms supportive niches for their clonal growth. We postulate that TF contributes to these interactions (directly or indirectly) through procoagulant and signaling effects, the latter executed in concert with juxtaposed protease activated receptors (mainly PAR-1 and PAR-2). TF/PAR system acts as a "blood sensing" mechanism, whereby cancer cells, including CSCs/TICs, may respond to plasma proteases (Factors VIIa, Xa, and IIa) and their related microenvironmental changes (fibrin deposition, activation of platelets). A growing body of still largely circumstantial evidence suggests that these events may contribute to the CSC/TIC niche, which could influence tumor initiation, metastasis, recurrence, and therapeutic intractability. Indeed, certain types of cancer cells harboring markers of CSCs (CD133) exhibit elevated TF expression and depend on this receptor to efficiently initiate tumor growth. We propose that both tumor cell-associated and host-related TF could influence the properties of CSCs, and that agents targeting the TF/PAR system may represent a hitherto unappreciated therapeutic opportunity to control cancer progression by influencing the CSC/TIC compartment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19628788     DOI: 10.1161/ATVBAHA.108.177444

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  17 in total

1.  Tissue Factor Regulation by miR-520g in Primitive Neuronal Brain Tumor Cells: A Possible Link between Oncomirs and the Vascular Tumor Microenvironment.

Authors:  Esterina D'Asti; Annie Huang; Marcel Kool; Brian Meehan; Jennifer A Chan; Nada Jabado; Andrey Korshunov; Stefan M Pfister; Janusz Rak
Journal:  Am J Pathol       Date:  2015-12-12       Impact factor: 4.307

2.  The pro-migratory and pro-invasive role of the procoagulant tissue factor in malignant gliomas.

Authors:  Stephan Dützmann; Florian Gessler; Patrick N Harter; Rüdiger Gerlach; Michel Mittelbronn; Volker Seifert; Donat Kögel
Journal:  Cell Adh Migr       Date:  2010 Oct-Dec       Impact factor: 3.405

3.  Thrombin drives tumorigenesis in colitis-associated colon cancer.

Authors:  Brian Turpin; Whitney Miller; Leah Rosenfeldt; Keith Kombrinck; Matthew J Flick; Kris A Steinbrecher; Eleana Harmel-Laws; Eric S Mullins; Maureen Shaw; David P Witte; Alexey Revenko; Brett Monia; Joseph S Palumbo
Journal:  Cancer Res       Date:  2014-04-07       Impact factor: 12.701

Review 4.  The cancer stem cell niche--there goes the neighborhood?

Authors:  Stephanie M Cabarcas; Lesley A Mathews; William L Farrar
Journal:  Int J Cancer       Date:  2011-09-14       Impact factor: 7.396

5.  Evaluation of procoagulant tissue factor expression in canine hemangiosarcoma cell lines.

Authors:  Lauren E Witter; Erika J Gruber; Fabian Z X Lean; Tracy Stokol
Journal:  Am J Vet Res       Date:  2017-01       Impact factor: 1.156

6.  PAR1 inhibition suppresses the self-renewal and growth of A2B5-defined glioma progenitor cells and their derived gliomas in vivo.

Authors:  R Auvergne; C Wu; A Connell; S Au; A Cornwell; M Osipovitch; A Benraiss; S Dangelmajer; H Guerrero-Cazares; A Quinones-Hinojosa; S A Goldman
Journal:  Oncogene       Date:  2015-11-30       Impact factor: 9.867

Review 7.  Tissue factor: past, present, and future.

Authors:  Nigel Mackman; Mark Taubman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-12       Impact factor: 8.311

8.  Immuno-PET of tissue factor in pancreatic cancer.

Authors:  Hao Hong; Yin Zhang; Tapas R Nayak; Jonathan W Engle; Hing C Wong; Bai Liu; Todd E Barnhart; Weibo Cai
Journal:  J Nucl Med       Date:  2012-09-17       Impact factor: 10.057

9.  Colon Cancer Growth and Dissemination Relies upon Thrombin, Stromal PAR-1, and Fibrinogen.

Authors:  Gregory N Adams; Leah Rosenfeldt; Malinda Frederick; Whitney Miller; Dusty Waltz; Keith Kombrinck; Kathryn E McElhinney; Matthew J Flick; Brett P Monia; Alexey S Revenko; Joseph S Palumbo
Journal:  Cancer Res       Date:  2015-08-03       Impact factor: 12.701

10.  Small but mighty: microparticles as mediators of tumor progression.

Authors:  Tali Voloshin; Ella Fremder; Yuval Shaked
Journal:  Cancer Microenviron       Date:  2014-04-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.